title: [Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].
abstract: The European Medicines Agency (EMA) recently approved the first anti-TNF-alpha biosimilar for infliximab (CT-P13) (trade names: Inflectra®and Remsima®) in Germany. Over the past year, German gastroenterologists gained experience treating IBD-patients with infliximab biosimilars (IFX-biosimilars). To evaluate their experiences and opinions on biosimilars, we conducted a nationwide online survey among German gastroenterologists. Our results are based on the assessment of 449 questionnaires. Although 61 % of the participants had already prescribed IFX-biosimilars, about two thirds of these participating gastroenterologists with IFX-biosimilar prescription stated their experience as based on fewer than 10 IBD-patients treated with IFX-biosimilars. Only 15 % considered themselves to be very experienced with biosimilars. The lower price in comparison to the originator is seen as the most important advantage of biosimilars (71 %). More than two thirds of the survey participants requested specific gastroenterological trials and registries to increase the data available on biosimilars in IBD-patients (68 %).
authors.affiliation: Gastroenterologische Gemeinschaftspraxis Minden, Minden.
authors.forename: Bernd
authors.initials: B
authors.lastname: Bokemeyer
authors.affiliation: Medizinische Klinik I, Agaplesion Markus Krankenhaus, Frankfurt/Main.
authors.forename: Axel
authors.initials: A
authors.lastname: Dignaß
authors.affiliation: Klinik Innere Medizin I, Universitätsklinik Schleswig-Holstein, Campus Kiel, Kiel.
authors.forename: Stefan
authors.initials: S
authors.lastname: Schreiber
mesh_terms: D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use*; D000072102:Gastroenterologists; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005858:Germany; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000628:therapy*; D000069285:Infliximab / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians'; D055656:Prescriptions; D011795:Surveys and Questionnaires; D014409:Tumor Necrosis Factor-alpha
chemical_list: D059451:Biosimilar Pharmaceuticals; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab